Ask VialBase
immune

Crystagen

Also known as: Crystagen peptide
Anecdotal evidence FDA: Not FDA-approved WADA: Not listed

Crystagen is a synthetic short peptide sold as a thymic/immune "Cytogen" in the Khavinson bioregulator family, marketed for immune support and anti-inflammatory effects in ageing. Unlike the better-studied Cytogens, no Crystagen-specific study is indexed in PubMed — its proposed epigenetic, immune-regulating mechanism is inferred from the broader short-peptide class. It is not FDA-approved. For educational purposes only. Not medical advice. Crystagen is presented as a thymus-tropic Cytogen whose proposed action — like the rest of the family — is epigenetic regulation of immune-tissue gene expression rather than receptor binding. Importantly, this mechanism is inferred by analogy, not demonstrated for Crystagen

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight —
Half-life ~minutes estimated;
CAS number —
Route Subcutaneous · Oral subcutaneous preferred
02

Mechanism

Synthetic short-peptide "Cytogen" marketed as a thymic/immune bioregulator. Like the other Khavinson Cytogens it is proposed to act epigenetically — modulating gene expression in immune tissue to support thymic function. Note: there is no Crystagen-specific peer-reviewed study; the mechanism is inferred from the broader short-peptide bioregulator class.

03

Dosing

DOSE RANGE 10–20 mg per cycle
FREQUENCY 1×/day
CYCLE LENGTH 10–20 days, cycled 2–3×/year

Traditional Khavinson-style pulsed cycles from practitioner protocols. No controlled dosing study exists for Crystagen specifically.

04

Research summary

Study Type Year Key Finding
Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results Clinical-studies review 2013 Summarises clinical results positioning Khavinson bioregulators as geroprotectors
Peptide Regulation of Gene Expression: A Systematic Review Systematic review 2021 Systematic review of how Khavinson short peptides regulate gene expression across tissues
05

Stacking & interactions

Thymic / immune support (Cytogen + thymic complex)

Layered immune bioregulation

Broader immune modulation

06

Sourcing

Stocks this compound Third-party tested Public COAs

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • CMP
  • CBC with differential
DURING CYCLE
  • CBC with differential
POST-CYCLE
  • CMP
  • CBC
Safety & Regulatory Status
FDA STATUS Not FDA-approved
WADA STATUS Not listed

Regulatory status for Crystagen may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.

Frequently Asked Questions

What is Crystagen?
Crystagen is a synthetic short peptide sold as a thymic/immune "Cytogen" in the Khavinson bioregulator family. It is marketed for immune support and anti-inflammatory effects in ageing or immunocompromised individuals.
Is there real research on Crystagen?
This is the honest part: there is no Crystagen-specific study indexed in PubMed — no clinical trial and no named in vitro paper. Its proposed epigenetic, immune-regulating mechanism is inferred from the broader Khavinson short-peptide class (peptide regulation of gene expression, geroprotector studies). Treat Crystagen's specific claims as unproven.
How does Crystagen differ from the better-studied Cytogens?
Vilon (KE), Livagen (KEDA), Vesugen (KED) and Epithalon all have at least named in vitro or human mechanistic studies. Crystagen does not — it has the weakest evidence base of the commonly sold Cytogens, resting on class analogy and vendor material rather than its own data.
How is Crystagen dosed?
Practitioner protocols use short pulsed courses of about 10–20 mg per cycle for 10–20 days, repeated two to three times a year, subcutaneously or orally. No controlled dosing study exists for Crystagen specifically.
Is Crystagen FDA-approved?
No. Crystagen is not FDA-approved and is sold only as a research chemical. Given the absence of compound-specific data, immune claims should be treated with particular caution.

References

  1. Khavinson VKh et al.. Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results. Adv Gerontol (2013). PMID: 24003726
  2. Khavinson VK et al.. Peptide Regulation of Gene Expression: A Systematic Review. Molecules (2021). PMID: 34834147